Balaji Amines Q4 FY26: Margin rebound funds a heavy FY27 project slate

Balaji Amines ended Q4 FY26 with a sharp step up in profitability, even as full-year revenue growth stayed modest. On a consolidated basis, revenue from operations rose to ₹403 crore in Q4 FY26, up from ₹361 crore in Q4 FY25 and ₹336 crore in Q3 FY26. The bigger story sat below the line. EBITDA expanded to ₹102 crore versus ₹68 crore a year ago, and profit after tax increased to ₹65 crore versus ₹40 crore in Q4 FY25. Diluted EPS for the quarter was ₹19.99, more than double the ₹9.49 reported in Q3 FY26.

For FY26, the company delivered steady top line progress with improving margins. Consolidated revenue was ₹1,454 crore (FY25 ₹1,430 crore) and EBITDA was ₹294 crore (FY25 ₹265 crore). PAT moved to ₹169 crore from ₹159 crore. The shift in mix, operating discipline, and timing of costs mattered more than volume growth in this cycle. The quarter also highlighted the balance Balaji Amines is trying to strike: capture a cyclical margin upswing in core amines and derivatives while funding a long pipeline of capacity and product additions across both the parent and its subsidiary.

Operationally, Q4 FY26 volumes were stable to improving. Total volumes were 27,341 MT versus 25,871 MT in Q4 FY25, supported by stable commodity prices and consistent demand across key segments. Segment volumes for Q4 FY26 were 7,746 MT in amines, 8,935 MT in amines derivatives, and 10,660 MT in specialty chemicals. This volume profile is important because Balaji Amines operates across a range of products that ultimately feed end markets like pharmaceuticals and agrochemicals. The presentation notes that globally about 61 percent of aliphatic amines and amine-based chemicals are consumed by pharmaceuticals, with 26 percent consumed by agrochemicals, making end-market health a critical driver for demand and realizations.

A notable point from management commentary is balance sheet posture. The company states it is a zero-debt company on a standalone basis. At the consolidated level, debt increased as projects moved through execution: consolidated debt stood at ₹133 crore in FY26 versus ₹11 crore in FY25. This is consistent with the cash flow statement that shows investing cash outflow of ₹344 crore for the year, funded partly by financing inflows of ₹85 crore, while cash and cash equivalents declined to ₹74 crore at March 2026 from ₹149 crore at March 2025.

Q4 FY26 performance: higher profitability on similar operating base

In Q4 FY26, consolidated revenue grew 11.71 percent year on year and 19.94 percent quarter on quarter. Costs were managed with a visible reduction in other expenses compared with the year-ago quarter. Consolidated other expenses were ₹53 crore in Q4 FY26 versus ₹72 crore in Q4 FY25, while raw material costs rose with the higher revenue base to ₹221 crore (Q4 FY25 ₹198 crore). EBITDA margin expanded to 25 percent in Q4 FY26 from 19 percent in Q4 FY25 and 18 percent in Q3 FY26.

Standalone results told the same story. Standalone revenue was ₹370 crore in Q4 FY26 versus ₹327 crore in Q4 FY25. Standalone EBITDA was ₹94 crore versus ₹64 crore, with EBITDA margin at 26 percent. Standalone PAT was ₹62 crore versus ₹40 crore, and EPS was ₹19.09.

The quarter’s improvement is best read as a margin normalization phase after a lower profitability period visible in the multi-year trend. Consolidated EBITDA margin was 27.27 percent in 2022, 26.34 percent in 2023, 21 percent in 2024, 18.5 percent in 2025, and 20.24 percent in 2026. Q4 FY26 at 25 percent suggests the business can still generate strong quarterly margins when operating conditions and cost lines cooperate, even if the full-year margin remains lower due to quarter-to-quarter variability.

What the volume mix says about the business

Balaji Amines organizes its operating footprint across amines, amine derivatives, and specialty and other chemicals. The Q4 FY26 volume split shows specialty chemicals at the highest tonnage (10,660 MT), followed by derivatives (8,935 MT) and amines (7,746 MT). This split matters because it speaks to the long-running strategy in the presentation: push downstream products based on the strength of amine manufacturing, where value addition and captive integration can protect margins.

The company also positions itself as a domestic leader in key product lines. It highlights being the largest manufacturer of aliphatic amines in India, the largest producer of methylamines in India, and the only company in India to develop an indigenous technology to manufacture amines. It also emphasizes that 80 percent of methylamines production is captively used, which can improve cost positioning when derivatives and specialty products are scaled.

Demand exposure is concentrated in essential end markets. Revenue breakup by industry is 65 percent pharma, 25 percent agrochemicals, and smaller contributions from oil and gas (3 percent), paints and resins (2 percent), animal feeds (2 percent), and other categories. This makes the company a proxy for two large Indian chemical consumption themes: pharmaceutical manufacturing and agrochemical formulations.

Exports are meaningful but not dominant at this stage. The company reports export revenue of ₹188.33 crore in FY26, representing 13.22 percent of total revenue, across multiple markets. The broader industry section notes that for Indian amine manufacturers, 45 to 55 percent of export revenue comes from Europe, and that methanol is a critical raw material often imported from the Middle East, underlining how supply chain reliability and logistics can shape margins.

Capital allocation: funding growth while holding the core steady

The presentation is explicit that new projects are planned to be completed with internal accruals, while the cash flow statement shows that FY26 was already capex heavy. Capital work in progress rose to ₹512 crore at March 2026 from ₹234 crore at March 2025 on the consolidated balance sheet. This is consistent with the near-term commissioning calendar.

Three near-term projects at the parent level anchor the FY27 pipeline. The Dimethyl Ether plant is expected to be commissioned during the first quarter of FY 2026-27, with capacity of 1,00,000 TPA as part of Phase 3 expansion. The company positions DME as a replacement for LPG for industrial and commercial usage and for aerosol applications. It also notes a regulatory and market backdrop: Bureau of Indian Standards has released standards to blend DME 20 percent with LPG, and oil marketing companies are considering blending up to 8 percent.

Alongside DME, N-Methyl Morpholine of 5,000 TPA is under execution and expected to be commissioned during FY 2026-27. The upgraded Acetonitrile plant, based on an improved process, is expected to be commissioned during the second quarter of FY 2026-27. Balaji Amines also notes that it executed MIPA and DIPA in Q1 FY26 and is upgrading its acetonitrile technology for improved cost economics and higher grades.

The subsidiary Balaji Specialty Chemicals is the other major capex leg. The company describes a ₹750 crore expansion in a phased manner, supported by Mega Project status under PSI 2019 from the Government of Maharashtra. The product list is wide and includes hydrogen cyanide, sodium cyanide in solution and pellets, EDTA and EDTA-2Na, and further EDA-based value-added products such as DELTA, TETA, PIP, AEEA, and AEP.

The timeline is staged. At Unit I, the brownfield project for EDA-based products with an additional reactor is expected to be commissioned during the first half of FY 2026-27. At Unit II, the greenfield project at MIDC Chincholi is in erection and installation, with commissioning of HCN, NaCN, EDTA, and EDTA-2Na expected in Q4 of FY 2026-27.

This expansion plan shows why consolidated debt and working capital metrics deserve attention. In FY26, operating cash flow decreased as working capital absorbed cash. Net cash from operating activities was ₹184 crore, down from ₹255 crore in FY25, while changes in working capital were negative ₹59 crore versus positive ₹53 crore in the prior year. Trade receivables increased to ₹346 crore at March 2026 from ₹275 crore at March 2025, while cash and cash equivalents reduced to ₹74 crore.

Yet the company’s ROCE discussion suggests that the core chemical business is still producing solid returns even while new plants remain under development. Core chemical business ROCE was 13 percent in FY26 versus 12 percent in FY25, while ROCE at the consolidated entity level was 14 percent versus 11 percent. Management also notes that capital work in progress includes DME, upgraded ACN, and NMM, and that BSCL’s capex is directed to greenfield and brownfield expansions.

Competitive position: integration, approvals, and selective import substitution

Balaji Amines frames its competitiveness around an integrated value chain, strong logistics for safe handling of aliphatic amines, and end-user preference for local sourcing due to safety considerations. It also highlights barriers to entry in the industry: complex manufacturing, high technical expertise, and lengthy approval processes for niche products. These factors help incumbent manufacturers maintain pricing relevance across cycles.

The company’s capacity table reinforces how broad the platform already is and how it is widening. After expansions, total capacity for the parent is shown at 4,15,100 TPA, up from existing 2,93,600 TPA. The largest single addition is DME at 1,00,000 TPA. ACN capacity is slated to double from 9,000 TPA to 18,000 TPA. DMAHCL and DMAC expand from 31,000 TPA to 38,500 TPA. NMM is added at 5,000 TPA.

BSCL’s own expansion is also material. Proposed capacity additions of 57,000 TPA increase total to 1,02,330 TPA, with products such as hydrogen cyanide at 10,000 TPA and sodium cyanide pellets at 12,000 TPA. These are large, regulated products where execution and compliance matter.

On ESG, the company notes a solar power plant of 8 MW DC (6 MW AC) commissioned as part of a net zero strategy and to reduce carbon footprint. It also states that phase 1 of a planned 20 MW greenfield solar power plant has commissioned 6 MW.

Investor takeaways: a profitable quarter, a capex-heavy year, and execution risk to watch

Balaji Amines enters FY27 with two things visible at once. First, Q4 FY26 demonstrated that earnings power can rebound quickly when operations stabilize, with consolidated EBITDA margin at 25 percent and PAT up 63 percent year on year. Second, the balance sheet and cash flows show that the business is in the middle of a large investment cycle. Investing cash flow outflow of ₹344 crore in FY26 and a sharp rise in capital work in progress indicate that the coming quarters will be defined by commissioning, ramp-up, and working capital control.

The central theme of the quarter is disciplined execution. Multiple projects have clear timelines: DME in Q1 FY 2026-27, upgraded ACN in Q2 FY 2026-27, NMM during FY 2026-27, and BSCL’s brownfield and greenfield blocks through the year, including Unit II expected in Q4 FY 2026-27. If these plants ramp as planned, the company’s strategy of moving up the value chain through derivatives and specialty products should have more room to show up in margins and returns.

For investors, the focus areas remain straightforward. Track whether quarterly margins remain closer to the Q4 FY26 level or revert to the FY26 average. Watch working capital as receivables have risen and cash has reduced. And watch how consolidated debt evolves as capex converts into operating assets. The presentation suggests the company is building a larger and more diversified platform, but the quality of execution through FY27 will determine how quickly this investment cycle turns into consistent earnings growth.